Cellenion Announces Co-Marketing Agreement with Bruker to Deliver Advanced Solutions for Single Cell Mass Spectrometry-Based Proteomics Analysis

The partnership with Bruker will provide scientists with a complete workflow, from single cell isolation and sample preparation to results, for label-free single cell proteomics analyses.


Cellenion, a  BICO company, announced today a co-marketing agreement with Bruker to advance label-free single cell proteomics analyses. The goal of this partnership is to combine Cellenion’s cellenONE® single cell isolation and dispensing platform with Bruker’s timsTOF SCP mass spectrometers to deliver end-to-end label-free single cell 4D-proteomics solution. The combination of these two instruments will allow automated sample preparation from single cell isolation to Mass Spectrometry (MS)-based proteomics analysis on single cells.


Cellenion has developed cellenONE®, a unique single-cell isolation and nanoliter dispensing technology allowing high throughput image-based dispensing of individual cells from cell suspensions and precision dispensing of reagents to automate and miniaturize sample preparation prior to single cells analyses.


Dr. Holger Eickhoff, CEO of Cellenion and SCIENION, BICOs Business Area Director Bioautomation, said, “We believe our expertise in precision dispensing and platform technology for up to 100% single cells isolation accuracy and Bruker’s expertise in developing mass spectrometers such as the timsTOF SCP for single cell proteomics are a perfect match. This partnership will benefit our mutual users as the cellenONE provides automated single cell isolation and miniaturized sample preparation using our patented nanoliter dispensing technology.”


Dr. Rohan Thakur, Executive Vice President, Life Sciences Mass Spectrometry at Bruker, said, “We are excited to partner with Cellenion and their cellenONE platform. This partnership of unique technologies provides our users with the ability to simplify and standardize single cell 4D-proteomics workflows. This is important because it allows researchers to contrast knowledge learned from decades of bulk proteomics to new discoveries being made in single cell proteomics using the cellenONE together with the timsTOF SCP system.”


For more information about Cellenion’s single cell mass spectrometry-based proteomics offering, please visit: www.cellenion.com/applications/single-cell-proteomics/


PR Contact

BICO Press office
Phone (US)
Riley Munks, PR Manager (650) 863-6699
Alyssa D’Orazio, PR Manager (617) 634-9601
Email: press@bico.com


About Cellenion

Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell and single cellular aggregates isolation. Our systems allow high throughput, image-based automated dispensing of single cells and/or cell aggregates onto any substrates of choice. Together with a range of dedicated consumables, the solutions enable miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volumes and outstanding recovery rates, Cellenion’s platforms offer unique capacities for applications including single-cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.


About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.


With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.


The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com


Cellenion Contact

Cellenion SASU
60 Avenue Rockefeller
Bioserra 2
F-69008 Lyon
Phone: +33 (0)9 86 48 70 70
E-mail: contact@cellenion.com

More News